B cell and aquaporin-4 antibody relationships with neuromyelitis optica spectrum disorder activity.

Autor: Bennett JL; Departments of Neurology and Ophthalmology, Programs in Neuroscience and Immunology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, Colorado, USA., Pittock SJ; Neurology, Laboratory Medicine and Pathology, Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, Minnesota, USA., Paul F; Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine and Charité - Universitätsmedizin, Berlin, Germany., Kim HJ; Department of Neurology, Research Institute and Hospital of National Cancer Center, Goyang, Republic of Korea., Irani SR; Oxford Autoimmune Neurology Group, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.; Department of Neurology, Mayo Clinic, Jacksonville, Florida, USA., O'Connor KC; Department of Neurology and Immunobiology, Yale School of Medicine, New Haven, Connecticut, USA., Patterson KR; Horizon Therapeutics (now Amgen Inc., Thousand Oaks, California, USA), Gaithersburg, Maryland, USA., Smith MA; Horizon Therapeutics (now Amgen Inc., Thousand Oaks, California, USA), Gaithersburg, Maryland, USA., Gunsior M; Horizon Therapeutics (now Amgen Inc., Thousand Oaks, California, USA), Gaithersburg, Maryland, USA., Mittereder N; Horizon Therapeutics (now Amgen Inc., Thousand Oaks, California, USA), Gaithersburg, Maryland, USA., Rees WA; Horizon Therapeutics (now Amgen Inc., Thousand Oaks, California, USA), Gaithersburg, Maryland, USA., Cimbora D; Horizon Therapeutics (now Amgen Inc., Thousand Oaks, California, USA), Gaithersburg, Maryland, USA., Cree BAC; UCSF Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, California, USA.
Jazyk: angličtina
Zdroj: Annals of clinical and translational neurology [Ann Clin Transl Neurol] 2024 Oct; Vol. 11 (10), pp. 2792-2798. Date of Electronic Publication: 2024 Sep 02.
DOI: 10.1002/acn3.52171
Abstrakt: This post hoc analysis of the randomized, placebo-controlled N-MOmentum study (NCT02200770) of inebilizumab in neuromyelitis optica spectrum disorder (NMOSD) evaluated relationships between circulating B-cell subsets and aquaporin-4 immunoglobulin G (AQP4-lgG) titers and attacks. Among participants receiving placebo, CD20 + and CD27 + B-cell counts were modestly increased from the pre-attack visit to attack; plasmablast/plasma cell gene signature was increased from baseline to the pre-attack visit (p = 0.016) and from baseline to attack (p = 0.009). With inebilizumab treatment, B-cell subset counts decreased and did not increase with attacks. No difference in change of AQP4-IgG titers from baseline to time of attack was observed.
(© 2024 The Author(s). Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje